Which of the following GLP – 1 analogue is cardioprotective?
**Core Concept**
GLP-1 analogues are a class of medications that mimic the action of the incretin hormone glucagon-like peptide-1 (GLP-1). They are primarily used to treat type 2 diabetes mellitus by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. However, some GLP-1 analogues have been found to possess cardioprotective properties, which include reducing mortality and morbidity in patients with heart failure.
**Why the Correct Answer is Right**
The cardioprotective effect of GLP-1 analogues is thought to be mediated through their ability to activate the GLP-1 receptor, which is expressed in the heart, blood vessels, and kidneys. Activation of the GLP-1 receptor triggers a series of downstream signaling pathways that ultimately lead to improved cardiovascular function, reduced inflammation, and decreased fibrosis. Specifically, GLP-1 analogues have been shown to reduce cardiac remodeling, improve left ventricular function, and decrease the risk of cardiovascular events.
**Why Each Wrong Option is Incorrect**
**Option A:** This GLP-1 analogue is not known for its cardioprotective effects. It is primarily used for glycemic control and weight loss.
**Option B:** This GLP-1 analogue has been associated with an increased risk of pancreatitis, but it does not possess cardioprotective properties.
**Option C:** This GLP-1 analogue has a different pharmacological profile and is not known for its cardioprotective effects.
**Clinical Pearl / High-Yield Fact**
When choosing a GLP-1 analogue for a patient with type 2 diabetes, it is essential to consider their cardiovascular risk profile and comorbidities, as some GLP-1 analogues may offer additional cardioprotective benefits.
**Correct Answer: C. Liraglutide**